Nanjing Leads Biolabs' Cancer Therapy Gets Orphan Drug Status in Japan; Shares Fall 5%
MT Newswires Live
Sep 28
Nanjing Leads Biolabs (HKG:9887) said its cancer treatment, LBL-024, has received orphan drug status in Japan, according to a Monday bourse filing.
The biotechnology company said its treatment has now been assigned the special designation in three key markets, including the United States and Europe.
The latest move by Japanese health regulators will make the drug eligible for various incentives in the country and help in bringing the treatment faster to commercial markets.
Shares were last down nearly 5% in afternoon trading
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.